about
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsHeat shock protein 90 inhibition: rationale and clinical potential.FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaComputer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.Online nanoflow multidimensional fractionation for high efficiency phosphopeptide analysisTargeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.Targeting Hsp90: small-molecule inhibitors and their clinical development.Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.Mechanisms of resistance to FLT3 inhibitors.Lestaurtinib: a multi-targeted FLT3 inhibitor.The clinical development of FLT3 inhibitors in acute myeloid leukemia.FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignanciesWill FLT3 inhibitors fulfill their promise in acute meyloid leukemia?Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseTyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.Optimized Orbitrap HCD for quantitative analysis of phosphopeptides.
P2860
Q24617091-F8BE942E-5ACB-4FAE-A756-3B58CCF5E83FQ30418761-DAC4A186-C45D-4F6D-A211-A7DED185503BQ33680292-69EC8CEC-5798-493D-AEAD-3202A398578DQ33854949-76EC2C1C-400A-4367-9FA1-F06D9D4C6D8DQ33879678-B79D6B62-A0C5-4B06-BE12-BFAC9A6F401CQ33943277-7BF66F36-53A1-4101-B476-0E01D61E5296Q35560182-4040CFF1-F34E-4754-A968-25329FB813F6Q35579649-ADE8C929-E95C-4799-97CD-F16B4F7730A6Q35687836-AEDDB3E6-774D-4303-9DDD-2A9EF5A2DE77Q36318153-DDC7DA18-A639-45C1-8E2B-B3D823F22857Q36322776-44118B6A-1009-4940-86ED-C37E3D4959D6Q36682854-985CB5DB-E91B-4AB5-8F47-571A1822F33FQ37222845-CE1B0A90-1F2B-4B40-A419-4FCBDBEA1671Q37234641-AC9137FF-BD66-436B-937D-41B49883BA3EQ37260555-F06ED83B-435C-456C-8256-434C4FA55DEBQ37375423-0C8180AB-3D40-4969-910E-6BCFAD4095E2Q37810104-F56E7627-E795-4982-8D70-EE69EDBF855BQ37927089-28440357-EDE9-4E89-9DE3-06C36E5B76C4Q38026453-6CB1C40C-0FC5-46F4-9957-7FEF64F7695AQ38166527-0775C8F3-3BB2-42CA-ADE2-6AB86250877BQ38182335-8BD6CBC2-DD18-4AB2-AD28-1F166AFF1FE3Q38272140-032704C8-1096-432F-B5B2-98C78456F6C0Q38853220-ACE66257-7B14-4465-A884-07EAF4C3F45DQ39448700-4AFD05DB-2261-4412-8145-577BDBD020FAQ42192063-E17EF604-F31E-4A49-9E1B-2C90C6E9556EQ47818563-13CF4764-558B-4811-AFB2-B398934B3A83Q47965368-42FDBE91-214A-4B1E-8505-6EFB04F2A1C7Q51835380-04E54035-994A-4841-901D-D01A940A0456
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
FLT3 inhibition in acute myeloid leukaemia.
@en
type
label
FLT3 inhibition in acute myeloid leukaemia.
@en
prefLabel
FLT3 inhibition in acute myeloid leukaemia.
@en
P1476
FLT3 inhibition in acute myeloid leukaemia.
@en
P2093
Steven Knapper
P304
P356
10.1111/J.1365-2141.2007.06700.X
P407
P577
2007-07-26T00:00:00Z